Web Analytics Made Easy - Statcounter

top of page

Multiple Myeloma Clinical Trials - @ Levine Cancer Institute

Levine Cancer Institute Myeloma Clinical Trials

NCT05347485

NCT05347485

NCT05014646

NCT05014646

7A2E19FA-5F33-4045-B0B2-693BD4E6948A

7A2E19FA-5F33-4045-B0B2-693BD4E6948A

NCT05347485

NCT05347485

1/24

Multiple Myeloma Clinical Trials Currently Recruiting

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma

2022 - NCT05463939

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

2022 - NCT05347485

Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients

2021 - NCT05014646

Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients

NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM

2021 - NCT04892446

Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM

NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

2021 - NCT04855136

Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

2021 - NCT04824794

Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

NCT04822337: Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma

2021 - NCT04822337

Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma

NCT04771078: Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial

2021 - NCT04771078

Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial

NCT04770402: Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients

2021 - NCT04770402

Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

2021 - NCT04722146

Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

2019 - NCT04133636

Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM

2019 - NCT04113018

Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM

United States - Myeloma Clinical Trials | MCT Index (themyelomaclinicaltrials.com)

bottom of page